Cargando…

The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro

BACKGROUND: Commercial fibrin glue is increasingly finding its way into clinical practice in surgeries to seal anastomosis, and initiate hemostasis or tissue repair. Human biological glue is also being discussed as a possible cell carrier. To date, there are only a few studies addressing the effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchs, Benedikt, Birt, Alexandra, Moellhoff, Nicholas, Kuhlmann, Constanze, Giunta, Riccardo, Wiggenhauser, Paul Severin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226008/
https://www.ncbi.nlm.nih.gov/pubmed/37082911
http://dx.doi.org/10.1177/08853282231171681
_version_ 1785050496201916416
author Fuchs, Benedikt
Birt, Alexandra
Moellhoff, Nicholas
Kuhlmann, Constanze
Giunta, Riccardo
Wiggenhauser, Paul Severin
author_facet Fuchs, Benedikt
Birt, Alexandra
Moellhoff, Nicholas
Kuhlmann, Constanze
Giunta, Riccardo
Wiggenhauser, Paul Severin
author_sort Fuchs, Benedikt
collection PubMed
description BACKGROUND: Commercial fibrin glue is increasingly finding its way into clinical practice in surgeries to seal anastomosis, and initiate hemostasis or tissue repair. Human biological glue is also being discussed as a possible cell carrier. To date, there are only a few studies addressing the effects of fibrin glue on the cell-molecular level. This study examines the effects of fibrin glue on angiogenesis and lymphangiogenesis, as well as adipose-derived stem cells (ASCs) with a focus on gene and protein expression in scaffolds regularly used for tissue engineering approaches. METHODS: Collagen-based dermal regeneration matrices (DRM) were seeded with human umbilical vein endothelial cells (HUVEC), human dermal lymphatic endothelial cells (LECs), or adipose-derived stem cells (ASC) and fixed with or without fibrin glue according to the experimental group. Cultures were maintained for 1 and 7 days. Finally, angiogenic and lymphangiogenic gene and protein expression were measured with special regard to subtypes of vascular endothelial growth factor (VEGF) and corresponding receptors using Multiplex-qPCR and ELISA assays. In addition, the hypoxia-induced factor 1-alpha (HIF1a) mediated intracellular signaling pathways were included in assessments to analyze a hypoxic encapsulating effect of fibrin polymers. RESULTS: All cell types reacted to fibrin glue application with an alteration of gene and protein expression. In particular, vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC), vascular endothelial growth receptor 1 (VEGFR1/FLT1), vascular endothelial growth receptor 2 (VEGFR2/KDR), vascular endothelial growth receptor 3 (VEGFR3/FLT4) and Prospero Homeobox 1 (PROX1) were depressed significantly depending on fibrin glue. Especially short-term fibrin effect led to a continuous downregulation of respective gene and protein expression in HUVECs, LECs, and ASCs. CONCLUSION: Our findings demonstrate the impact of fibrin glue application in dermal regeneration with special regard to angiogenesis and lymphangiogenesis. In particular, a short fibrin treatment of 24 hours led to a decrease in gene and protein levels of LECS, HUVECs, and ASCs. In contrast, the long-term application showed less effect on gene and protein expressions. Therefore, this work demonstrated the negative effects of fibrin-treated cells in tissue engineering approaches and could affect wound healing during dermal regeneration.
format Online
Article
Text
id pubmed-10226008
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102260082023-05-30 The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro Fuchs, Benedikt Birt, Alexandra Moellhoff, Nicholas Kuhlmann, Constanze Giunta, Riccardo Wiggenhauser, Paul Severin J Biomater Appl Soft Tissues and Materials BACKGROUND: Commercial fibrin glue is increasingly finding its way into clinical practice in surgeries to seal anastomosis, and initiate hemostasis or tissue repair. Human biological glue is also being discussed as a possible cell carrier. To date, there are only a few studies addressing the effects of fibrin glue on the cell-molecular level. This study examines the effects of fibrin glue on angiogenesis and lymphangiogenesis, as well as adipose-derived stem cells (ASCs) with a focus on gene and protein expression in scaffolds regularly used for tissue engineering approaches. METHODS: Collagen-based dermal regeneration matrices (DRM) were seeded with human umbilical vein endothelial cells (HUVEC), human dermal lymphatic endothelial cells (LECs), or adipose-derived stem cells (ASC) and fixed with or without fibrin glue according to the experimental group. Cultures were maintained for 1 and 7 days. Finally, angiogenic and lymphangiogenic gene and protein expression were measured with special regard to subtypes of vascular endothelial growth factor (VEGF) and corresponding receptors using Multiplex-qPCR and ELISA assays. In addition, the hypoxia-induced factor 1-alpha (HIF1a) mediated intracellular signaling pathways were included in assessments to analyze a hypoxic encapsulating effect of fibrin polymers. RESULTS: All cell types reacted to fibrin glue application with an alteration of gene and protein expression. In particular, vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC), vascular endothelial growth receptor 1 (VEGFR1/FLT1), vascular endothelial growth receptor 2 (VEGFR2/KDR), vascular endothelial growth receptor 3 (VEGFR3/FLT4) and Prospero Homeobox 1 (PROX1) were depressed significantly depending on fibrin glue. Especially short-term fibrin effect led to a continuous downregulation of respective gene and protein expression in HUVECs, LECs, and ASCs. CONCLUSION: Our findings demonstrate the impact of fibrin glue application in dermal regeneration with special regard to angiogenesis and lymphangiogenesis. In particular, a short fibrin treatment of 24 hours led to a decrease in gene and protein levels of LECS, HUVECs, and ASCs. In contrast, the long-term application showed less effect on gene and protein expressions. Therefore, this work demonstrated the negative effects of fibrin-treated cells in tissue engineering approaches and could affect wound healing during dermal regeneration. SAGE Publications 2023-04-21 2023-05 /pmc/articles/PMC10226008/ /pubmed/37082911 http://dx.doi.org/10.1177/08853282231171681 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Soft Tissues and Materials
Fuchs, Benedikt
Birt, Alexandra
Moellhoff, Nicholas
Kuhlmann, Constanze
Giunta, Riccardo
Wiggenhauser, Paul Severin
The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro
title The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro
title_full The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro
title_fullStr The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro
title_full_unstemmed The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro
title_short The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro
title_sort use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro
topic Soft Tissues and Materials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226008/
https://www.ncbi.nlm.nih.gov/pubmed/37082911
http://dx.doi.org/10.1177/08853282231171681
work_keys_str_mv AT fuchsbenedikt theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT birtalexandra theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT moellhoffnicholas theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT kuhlmannconstanze theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT giuntariccardo theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT wiggenhauserpaulseverin theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT fuchsbenedikt useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT birtalexandra useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT moellhoffnicholas useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT kuhlmannconstanze useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT giuntariccardo useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro
AT wiggenhauserpaulseverin useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro